ROXANA-CLEOPATRA PENCIU, LILIANA STERIU, SILVIA IZVORANU, IULIA POSTOLACHE, ANDREI-ADRIAN TICA, DIANA MOCANU, OANA-SORINA TICA, VASILE SARBU, MARIANA DEACU, GABRIELA BALTATESCU, IRINA TICA, LUCIAN PETCU, VLAD-IUSTIN TICA CD10, CD34 AND KI67 IMMUNOHISTOCHEMICAL MARKERS EXPRESSION IN ENDOMETRIOSIS AND ADENOMYOSIS Endometriosis is a benign disease represented by existence of endometrial tissue outside the uterine cavity. Considered in the past a type of endometriosis, adenomyosis is, presently, described as a possible different entity, comparative to endometriosis. That is the reason why we decided to study two groups of patients - one with endometriosis and one with adenomyosis - in order to determine if they are one and the same disease. We included all successive patients admitted and surgically treated in the Emergency Clinical Hospital Constanta between 2015-2017, and, after applying the selection criteria, we assessed 61 patients (group 1) diagnosed with endometriosis - ovarian, cervical, caesarian section scar - and 39 patients (group 2) with adenomyosis. We studied all patients in terms of age, parity, lesions’ size, admissions’ symptoms, chronic symptoms and immunohistochemical markers CD10, CD34, Ki67. We chose there three markers because of their possible relation to endometriosis and because we were unable to find data regarding the comparison of CD34 or Ki67 expression in endometriosis and adenomyosis and because we did not find articles that reported the expression of these three immunohistochemical markers, combined, for either endometriosis or adenomyosis. According to our study, it seems that endometriosis and adenomyosis are different clinically with regard of age and dysmenorrhea, but there was no statistical difference between the studied immunohistochemical biomarkers’ expression in samples of patients with endometriosis or adenomyosis.